Chemistry:Preladenant
From HandWiki
Revision as of 15:20, 30 June 2021 by imported>NBrushPhys (simplify)
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C25H29N9O3 |
| Molar mass | 503.567 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease.[1] Positive results were reported in Phase II clinical trials in humans,[2] but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.[3]
References
- ↑ "Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 in Rodent Models of Movement Disorders and Depression". The Journal of Pharmacology and Experimental Therapeutics 330 (1): 294–303. March 2009. doi:10.1124/jpet.108.149617. PMID 19332567.
- ↑ Hauser, R. A.; Cantillon, M.; Pourcher, E.; Micheli, F.; Mok, V.; Onofrj, M.; Huyck, S.; Wolski, K. (2011). "Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial". The Lancet Neurology 10 (3): 221–229. doi:10.1016/S1474-4422(11)70012-6. PMID 21315654.
- ↑ http://bigstory.ap.org/article/merck-ends-development-parkinsons-disease-drug
 |  |
